fbpx
  • Home
  • Study Details
Open

Clinical trial of alvelestat in alpha-1 antitrypsin patients

The purpose of the study is to test how a new drug called Alvelestat affects the signs of lung damage caused by Alpha-1 antitrypsin deficiency (AATD). AATD is a rare genetic condition that can cause Chronic Obstructive Pulmonary Disease (COPD.)

Age & Gender

  • 25 years ~ 80 years
  • Male, Female

Location

North Carolina (Statewide)

What will be asked of you

1-2 Screening, 1 eye exam, 1 CAT scan, 1 randomization, 9 follow-up visits, 3 phone visits

Incentives

$50-$100 per study visit. Total compensation $830

In-person visits : 14
Phone or online visits : 3
Total length of participation : Up to 6 months (3 months of medication)

Looking for Specific Volunteers

Able to participate:

  • Confirmed diagnosis of alpha-1 antitrypsin deficiency

Not eligible if:

  • Pregnant or plan to become pregnant
  • History of cirrhosis, hepatitis or HIV
  • History of heart failure

Contact the Team

Visit Location

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

Brad Drummond
Medicine-Pulmonary

Study Topics

Genetics and Genetic Disorders
Lungs and Breathing

IRB Number

19-2677

logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.